Abstract

The objective of the Multicenter Study of Hydroxyurea (MSH) Follow-up is to establish a follow-up study of the adult patients who participated in the Multicenter Study of Hydroxyurea in Sickle Cell Disease (MSH) in order to ascertain the long term toxic effects of hydroxyurea usage in this patient population. Prior to the MSH, hydroxyurea had never been used at this dosage in this patient population. The patients will be followed annually to determine health status, quality of life, incidence of malignancies, and birth defects in their offspring. in addition, mortality rates will be determined so that a comparison can be made between this cohort and the mortality data from the Cooperative Study of Sickle Cell Disease (CSSCD) adult cohort and the normal African-American population mortality data.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
Division of Blood Diseases And Resources (NHLBI)
Type
Research and Development Contracts (N01)
Project #
N01HB067129-003
Application #
2798876
Study Section
Project Start
1996-02-01
Project End
2001-01-31
Budget Start
1998-05-04
Budget End
1999-04-30
Support Year
Fiscal Year
1998
Total Cost
Indirect Cost

  Institution

Name
Maryland Medical Research Institute, Inc
Department
Type
DUNS #
069392181
City
Baltimore
State
MD
Country
United States
Zip Code
21210

  Publications

Smith, Wally R; Ballas, Samir K; McCarthy, William F et al. (2011) The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Med 12:697-705
Ballas, Samir K; Bauserman, Robert L; McCarthy, William F et al. (2010) The impact of hydroxyurea on career and employment of patients with sickle cell anemia. J Natl Med Assoc 102:993-9
Ballas, Samir K; Bauserman, Robert L; McCarthy, William F et al. (2010) Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. J Pain Symptom Manage 40:870-82
Ballas, Samir K; McCarthy, William F; Guo, Nan et al. (2010) Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin 34:424-9
Steinberg, Martin H; McCarthy, William F; Castro, Oswaldo et al. (2010) The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 85:403-8
Smith, Wally R; Bauserman, Robert L; Ballas, Samir K et al. (2009) Climatic and geographic temporal patterns of pain in the Multicenter Study of Hydroxyurea. Pain 146:91-8
Ballas, Samir K; Barton, Franca B; Waclawiw, Myron A et al. (2006) Hydroxyurea and sickle cell anemia: effect on quality of life. Health Qual Life Outcomes 4:59
Steinberg, Martin H; Barton, Franca; Castro, Oswaldo et al. (2003) Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 289:1645-51